Seminars in Nephrology
Volume 25, Issue 4 , Pages 236-245 , July 2005

Hypertension and the Kidney

  • Michael Wiederkehr

      Affiliations

    • Baylor University Medical Center; Dallas Nephrology Associates; Dallas Texas
    • Corresponding Author InformationAddress reprint requests to Michael Wiederkehr, MD, 3601 Swiss Ave, Dallas, TX 75204-6225
    • ,
  • Robert Toto

      Affiliations

    • University of Texas Southwestern Medical School; Division of Nephrology; Dallas, Texas
    • ,
  • Andrew Z. Fenves

      Affiliations

    • Baylor University Medical Center; Dallas Nephrology Associates; Dallas Texas
    • ,
  • C. Venkata S. Ram

      Affiliations

    • Texas Blood Pressure Institute; Dallas Nephrology Associates; University of Texas Southwestern Medical School; Dallas, Texas

References 

  1. Hyman DJ , Pavlik VN . Characteristics of patients with uncontrolled hypertension in the United States . N Engl J Med . 2001;345:479–486
  2. Prevalence of chronic kidney disease and decreased kidney function in the adult U.S. population (Third National Health and Nutrition Examination Survey) . Am J Kidney Dis . 2003;41(suppl 2):S29–S40
  3. Coresh J , Astor BC , Greene T , et al.   Prevalence of chronic kidney disease and decreased kidney function in the adult US population (Third National Health and Nutrition Examination Survey) . Am J Kidney Dis . 2003;41:1–12
  4. Bakris GL . Maximizing cardio-renal benefits (Achieving blood pressure goals) . J Clin Hypertens . 1999;41:141–148
  5. Klag MJ , Whelton PK , Randall BL , et al.   Blood pressure and end-stage renal disease in men . N Engl J Med . 1996;334:13–18
  6. National Kidney Foundation . K/DOQI Clinical Practice Guidelines on hypertension and antihypertensive agents in chronic kidney disease . Am J Kidney Dis . 2004;43(suppl 1):S65–S223
  7. United National Institutes of Health . US Renal Data System. USRDS 2003 Annual Data Report . Maryland: Bethesda; 2003;
  8. UKPDS Study Group . Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group . BMJ . 1998;317:713–720
  9. Ljungman S , Wikstrand J , Hartford M , et al.   Urinary albumin excretion—a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men . Am J Hypertens . 1996;9:770–778
  10. Sacks FM , Svetkey LP , Vollmer WM , et al.   Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group . N Engl J Med . 2001;344:3–10
  11. Ruiz-Ortega M , Lorenzo O , Suzuki Y , et al.   Proinflammatory actions of angiotensins . Curr Opin Nephrol Hypertens . 2001;10:321–329
  12. Lewis EJ , Hunsicker LG , Bain RP , et al.   The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy . N Engl J Med . 1993;329:1456–1462
  13. The Hope Trial Investigators . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators . Lancet . 2000;22:355:253–259
  14. Hansson L , Lindholm LH , Niskanen L , et al.   Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension (The Captopril Prevention Project (CAPPP) randomised trial) . Lancet . 1999;353:611–616
  15. Estacio RO , Jeffers BW , Hiatt WR , et al.   The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension . N Engl J Med . 1998;338:645–652
  16. Tatti P , Pahor M , Byington RP , et al.   Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM . Diabetes Care . 1998;21:597–603
  17. Yusuf S , Gerstein H , Hoogwerf B , et al.   Ramipril and the development of diabetes . JAMA . 2001;286:1882–1885
  18. Kon V , Fogo A , Ichikawa I . Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition . Kidney Int . 1993;44:545–550
  19. Parving HH , Lehnert H , Brochner-Mortensen J , et al.   The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes . N Engl J Med . 2001;345:870–878
  20. Lewis EJ , Hunsicker LG , Clarke WR , et al.   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . N Engl J Med . 2001;345:851–860
  21. Brenner BM , Cooper ME , de Zeeuw D , et al.   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy . N Engl J Med . 2001;345:861–869
  22. Yusuf S , Sleight P , Pogue J , et al.   Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators . N Engl J Med . 2000;342:145–153
  23. Moller JE , Dahlstrom U , Gotzsche O , et al.   Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction (Results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy) . Am Heart J . 2004;147:494–501
  24. Rembold CM . Losartan was more effective than atenolol for isolated systolic hypertension and left ventricular hypertrophy . ACP J Club . 2003;138:37
  25. Messerli FH . The LIFE study (The straw that should break the camel’s back) . Eur Heart J . 2003;24:487–489
  26. Mogensen CE , Neldam S , Tikkanen I , et al.   Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes (The candesartan and lisinopril microalbuminuria (CALM) study) . BMJ . 2000;321:1440–1444
  27. Jacobsen P , Andersen S , Rossing K , et al.   Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy . Nephrol Dial Transplant . 2002;17:1019–1024
  28. Jacobsen P , Andersen S , Jensen BR , et al.   Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy . J Am Soc Nephrol . 2003;14:992–999
  29. Laverman GD , Navis G , Henning RH , et al.   Dual renin-angiotensin system blockade at optimal doses for proteinuria . Kidney Int . 2002;62:1020–1025
  30. Jacobsen P , Andersen S , Rossing K , et al.   Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy . Kidney Int . 2003;63:1874–1880
  31. Rossing K , Jacobsen P , Pietraszek L , et al.   Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy (A randomized double-blind crossover trial) . Diabetes Care . 2003;26:2268–2274
  32. Chrysostomou A , Becker G . Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease . N Engl J Med . 2001;345:925–926
  33. Klisic J , Zhang J , Nief V , et al.   Albumin regulates the Na+/H+ exchanger 3 in OKP cells . J Am Soc Nephrol . 2003;14:3008–3016
  34. Klahr S , Levey AS , Beck GJ , et al.   The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group . N Engl J Med . 1994;330:877–884
  35. Gissen Group . Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) . Lancet . 1997;349:1857–1863
  36. Ruggenenti P , Perna A , Gherardi G , et al.   Chronic proteinuric nephropathies (Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury) . Am J Kidney Dis . 2000;35:1155–1165
  37. Wright JT , Bakris G , Greene T , et al.   Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease (results from the AASK trial) . JAMA . 2002;288:2421–2431
  38. Maschio G , Alberti D , Janin G , et al.   Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group . N Engl J Med . 1996;334:939–945
  39. Ruggenenti P , Perna A , Gherardi G , et al.   Renoprotective properties of ACEIs inhibition in non-diabetic nephropathies with non-nephrotic proteinuria . Lancet . 1999;354:359–364
  40. Schrier R , McFann K , Johnson A , et al.   Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease (Results of a seven-year prospective randomized study) . J Am Soc Nephrol . 2002;13:1733–1739
  41. van Dijk MA , Breuning MH , Duiser R , et al.   No effect of enalapril on progression in autosomal dominant polycystic kidney disease . Nephrol Dial Transplant . 2003;18:2314–2320
  42. Ecder T , Chapman AB , Brosnahan GM , et al.   Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease . Am J Kidney Dis . 2000;35:427–432
  43. Nakamura T , Ushiyama C , Shimada N , et al.   Effects of the angiotensin II receptor antagonist candesartan cilexetil on blood pressure and proteinuria in patients with autosomal dominant polycystic kidney disease . Nephron . 2000;86:385–386
  44. Luno J , Barrio V , Goicoechea MA , et al.   Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies . Kidney Int . 2002;62(suppl 82):47–52
  45. Nakao N , Yoshimura A , Morita H , et al.   Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) (A randomised controlled trial) . Lancet . 2003;361:117–124
  46. Rutkowski P , Tylicki L , Renke M , et al.   Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis . Am J Kidney Dis . 2004;43:260–268
  47. Campbell R , Sangalli F , Perticucci E , et al.   Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies . Kidney Int . 2003;63:1094–1103
  48. Cohn JN , Tognoni G . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure . N Engl J Med . 2001;345:1667–1675
  49. Pfeffer MA , McMurray JJ , Velazquez EJ , et al.   Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both . N Engl J Med . 2003;349:1893–1906
  50. Williams GH , Burgess E , Kolloch RE , et al.   Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension . Am J Cardiol . 2004;93:990–996
  51. Shulman NB , Ford CE , Hall WD , et al.   Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group . Hypertension . 1989;13:I80–I93
  52. United National Institutes of Health . US Renal Data System. USRDS 2001 Annual Data Report. 12th Annual Report . Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2001;
  53. Agodoa LY , Appel L , Bakris GL , et al.   Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis (A randomized controlled trial) . JAMA . 2001;285:2719–2728
  54. Cowie CC , Port FK , Wolfe RA , et al.   Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes . N Engl J Med . 1989;321:1074–1079
  55. McClellan W , Tuttle E , Issa A . Racial differences in the incidence of hypertensive end-stage renal disease are not entirely explained by differences in the prevalence of hypertension . Am J Kidney Dis . 1988;12:285–290
  56. Lopes AA , Port FK , James SA , et al.   The excess risk of treated end-stage renal disease in blacks in the United States . J Am Soc Nephrol . 1993;3:1961–1971
  57. Perneger TV , Klag MJ , Whelton PK . Race and socioeconomic status in hypertension and renal disease . Curr Opin Nephrol Hypertens . 1995;4:235–239
  58. Blythe WD , Maddux FW . Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States from 1980–1986 . Am J Kidney Dis . 1991;28:33–37
  59. Perneger TV , Nieto FJ , Whelton PK , et al.   A prospective study of blood pressure and serum creatinine. Results from the ‘Clue’ study and the ARIC study . JAMA . 1993;269:488–493
  60. Perneger TV , Whelton PK , Puddey IB , et al.   Risk of end-stage renal disease associated with alcohol consumption . Am J Epidemiol . 1999;150:1275–1281
  61. Brancati FL , Whittle JC , Whelton PK , et al.   The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors . JAMA . 1992;268:3079–3084
  62. Klag MJ , Whelton PK , Randall BL , et al.   End-stage renal disease in African-American and white men. 16-year MRFIT findings . JAMA . 1997;277:1293–1298
  63. Brenner BM . Hemodynamically mediated glomerular injury and the progressive nature of kidney disease . Kidney Int . 1983;23:647–655
  64. Brenner BM , Chertow GM . Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury . Am J Kidney Dis . 1994;23:171–175
  65. Powe NR . Early referral in chronic kidney disease (An enormous opportunity for prevention) . Am J Kidney Dis . 2003;41:505–507
  66. Powe NR , Tarver-Carr ME , Eberhardt MS , et al.   Receipt of renal replacement therapy in the United States (A population-based study of sociodemographic disparities from the Second National Health and Nutrition Examination Survey (NHANES II)) . Am J Kidney Dis . 2003;42:249–255
  67. Tarver-Carr ME , Powe NR , Eberhardt MS , et al.   Excess risk of chronic kidney disease among African-American versus white subjects in the United States (A population-based study of potential explanatory factors) . J Am Soc Nephrol . 2002;13:2363–2370
  68. Muntner P , Coresh J , Smith JC , et al.   Plasma lipids and risk of developing renal dysfunction (The atherosclerosis risk in communities study) . Kidney Int . 2000;58:293–301
  69. Muntner P , He J , Hamm L , et al.   Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States . J Am Soc Nephrol . 2002;13:745–753
  70. Muntner P , Garrett E , Klag MJ , et al.   Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age . Stroke . 2002;33:1209–1213
  71. Muntner P , Hamm LL , Kusek JW , et al.   The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease . Ann Intern Med . 2004;140:9–17
  72. Young JH , Klag MJ , Muntner P , et al.   Blood pressure and decline in kidney function (Findings from the Systolic Hypertension in the Elderly Program (SHEP)) . J Am Soc Nephrol . 2002;13:2776–2782
  73. Perry HM , Miller JP , Fornoff JR , et al.   Early predictors of 15-year end-stage renal disease in hypertensive patients . Hypertension . 1995;25:587–594
  74. Burton C , Harris KP . The role of proteinuria in the progression of chronic renal failure . Am J Kidney Dis . 1996;27:765–775
  75. Jafar TH , Stark PC , Schmid CH , et al.   Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis . Ann Intern Med . 2003;139:244–252
  76. Jafar TH , Schmid CH , Landa M , et al.   Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data . Ann Intern Med . 2001;135:73–87
  77. Toto RD . Hypertensive nephrosclerosis. Nephrology forum . Kidney Int . 2003;64:2331–2341
  78. Jafar TH , Stark PC , Schmid CH , et al.   Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease . Kidney Int . 2001;60:1131–1140
  79. Wright JTJ , Kusek JW , Toto RD , et al.   Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study . Control Clin Trials . 1996;17:3S–16S
  80. Fogo A , Breyer JA , Smith MC , et al.  AASK Pilot Study Investigators   Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans (A report from the African American Study of Kidney Disease (AASK) Trial) . Kidney Int . 1997;51:244–252
  81. Regalado M , Yang S , Wesson DE . Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension . Am J Kidney Dis . 2000;35:687–694
  82. Ritz E , Ogata H , Orth SR . Smoking (A factor promoting onset and progression of diabetic nephropathy) . Diabet Med . 2000;26:54–63
  83. Mann JF , Gerstein HC , Pogue J , et al.   Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril (The HOPE randomized trial) . Ann Intern Med . 2001;134:629–636
  84. Gouva C , Nikolopoulos P , Ioannidis JP , et al.   Treating anemia early in renal failure patients slows the decline of renal function (A randomized controlled trial) . Kidney Int . 2004;66:753–760
  85. Grundy SM , Cleeman JI , Merz CN , et al.   Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel IIi guidelines . Circulation . 2004;110:227–239
  86. Mackenzie HS , Taal MW , Luycks VA , et al.   Adaptation to nephron loss . In:  Brenner BM editors. The Kidney . 6th ed.. Philadelphia: Saunders; 2000;p. 1901–1942
  87. UKPDS Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [published erratum appears in BMJ 318:29, 1999] . BMJ . 1998;317:703–713
  88. Hannedouche T , Landais P , Goldfarb B , et al.   Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure . BMJ . 1994;309:833–837
  89. Sheinfeld GR , Bakris GL . Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients . Am J Hypertens . 1999;12:80S–85S
  90. Bakris GL , Siomos M , Richardson D , et al.  VAL-K Study Group   ACE inhibition or angiotensin receptor blockade (Impact on potassium in renal failure) . Kidney Int . 2000;58:2084–2092
  91. Palmer BF . Renal dysfunction complicating the treatment of hypertension . N Engl J Med . 2002;347:1256–1261
  92. Bakris GL , Weir MR . Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine (Is this a cause for concern?) . Arch Intern Med . 2000;160:685–693
  93. Apperloo AJ , de Zeeuw D , de Jong PE . A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function . Kidney Int . 1997;51:793–797
  94. Perez-Oller L , Torra R , Badenas C , et al.   Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease . Am J Kidney Dis . 1999;34:273–278
  95. United National Institutes of Health . US Renal Data System. USRDS 2002 Annual Data Report . Maryland: Bethesda; 2003;
  96. Horl MP , Horl WH . Hemodialysis-associated hypertension (Pathophysiology and therapy) . Am J Kidney Dis . 2002;39:227–244
  97. Foley RN , Parfrey PS , Harnett JD , et al.   Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease . Kidney Int . 1996;49:1379–1385
  98. Agarwal R , Nissenson AR , Batlle D , et al.   Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States . Am J Med . 2003;115:291–297
  99. Lazar AE , Smith MC , Rahman M . Blood pressure measurement in hemodialysis patients . Semin Dial . 2004;17:250–254
  100. Leypoldt JK , Cheung AK , Delmez JA , et al.   Relationship between volume status and blood pressure during chronic hemodialysis . Kidney Int . 2002;61:266–275
  101. Horl MP , Horl WH . Drug therapy for hypertension in hemodialysis patients . Semin Dial . 2004;17:288–294

PII: S0270-9295(05)00033-1

doi: 10.1016/j.semnephrol.2005.02.008

Seminars in Nephrology
Volume 25, Issue 4 , Pages 236-245 , July 2005

Article Tools

* Image Usage & Resolution